

The LEAP checklist for laboratory evaluation and analytical performance characteristics reporting of clinical measurement procedures

Tze Ping Loh^{*1}, Brian R Cooke², Thi Chi Mai Tran^{3,4}, Corey Markus⁵, Rosita Zakaria^{6,7}, Chung Shun Ho⁸, Elvar Theodorsson⁹, Ronda F Greaves^{*10,11}; on behalf of the IFCC Working Group on Method Evaluation Protocols (WG-MEP)

¹Department of Laboratory Medicine, National University Hospital, Singapore, Singapore

²Department of Clinical Biochemistry, PathWest Laboratory Medicine, Fiona Stanley Hospital, Murdoch, Australia

³Faculty of Medical Technology, Hanoi Medical University, Hanoi, Vietnam

⁴Department of Clinical Biochemistry, National Children's Hospital, Hanoi, Vietnam

⁵Flinders University International Centre for Point-of-Care Testing, Flinders Health and Medical Research Institute, Adelaide, Australia

⁶RMIT University, School of Health and Biomedical Sciences, Victoria, Australia

⁷Murdoch Children's Research Institute, Melbourne, Australia

⁸Department of Chemical Pathology, The Chinese University of Hong Kong, Prince of Wales Hospital, Shatin, Hong Kong

⁹Department of Biomedical and Clinical Sciences, Division of Clinical Chemistry and Pharmacology, Linköping University, SE-58183 Linköping, Sweden

¹⁰Department of Paediatrics, The University of Melbourne, Melbourne, Australia

¹¹Victorian Clinical Genetics Services, Murdoch Children's Research Institute, Parkville, Australia

*Corresponding author: tploh@hotmail.com; ronda.greaves@mcri.edu.au

Abstract

Reporting a measurement procedure and its analytical performance following method evaluation in a peer-reviewed journal is an important means for clinical laboratory practitioners to share their findings. It also represents an important source of evidence base to help others make informed decisions about their practice. At present, there are significant variations in the information reported in laboratory medicine journal publications describing the analytical performance of measurement procedures. These variations also challenge authors, readers, reviewers, and editors in deciding the quality of a submitted manuscript.

The International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Method Evaluation Protocols (IFCC WG-MEP) developed a checklist and recommends its adoption to enable a consistent approach to reporting method evaluation and analytical performance characteristics of measurement procedures in laboratory medicine journals. It is envisioned that the Laboratory Evaluation and Analytical Performance Characteristics (LEAP) checklist will improve the standardisation of journal publications describing method evaluation and analytical performance characteristics, improving the quality of the evidence base that is relied upon by practitioners.

Keywords: emerging technology(ies); method verification; method validation

Submitted: August 25, 2023

Accepted: September 18, 2023

Introduction

The reporting of a measurement procedure and its analytical performance following method evaluation in a peer-reviewed journal is an important means for clinical laboratory practitioners to share their findings. It represents an important source of evidence base to help others make informed decisions about their practice. These publications must

report the essential components of method evaluation and their analytical performance characteristics in a standardised, consistent manner to enable replication and to improve the generalisability of the findings (1). This will also facilitate the pooling of findings from individual studies e.g. for meta-analysis. At present, there are significant variations

<https://doi.org/10.11613/BM.2023.030505>

Biochem Med (Zagreb) 2023;33(3):030505

©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>) which permits users to read, download, copy, distribute, print, search, or link to the full texts of these articles in any medium or format and to remix, transform and build upon the material, provided the original work is properly cited and any changes properly indicated.

in the information reported in laboratory medicine journal publications describing the analytical performance of measurement procedures (2). These variations also challenge authors, readers, reviewers, and editors in deciding the quality of a submitted manuscript.

The International Federation of Clinical Chemistry and Laboratory Medicine Working Group on Method Evaluation Protocol (IFCC WG-MEP) aimed to develop a checklist and recommends its adoption to enable a consistent approach to reporting method evaluation and analytical performance characteristics of measurement procedures in laboratory medicine journals.

Methods

Checklist development

A draft checklist was developed by the IFCC WG-MEP following the recommendations and toolkit of the Enhancing the Quality and Transparency Of health Research (EQUATOR) Network (3). This draft was presented to the full WG-MEP, including corresponding members, at the annual meeting held during the IFCC WorldLab conference in Rome on 21st May 2023, and suggestions for improvements were incorporated into the submitted version. After extensive discussion and consensus agreement of the working group members, the checklist was finalised for multi-journal publication as an open-

access offering to allow for free dissemination and use by clinical laboratories, manufacturers, other related journals, editors, reviewers, readers, and authors.

Results

The Laboratory Evaluation and Analytical Performance Characteristics (LEAP) checklist is presented in Table 1. This table encompasses various main elements and requirements of method evaluation for clinical testing that should be included in a published paper. Authors are advised to adequately address and provide evidence for each item in the checklist to ensure that all necessary issues of method evaluation are fully addressed. Authors need to determine if the study involves method validation (e.g. when describing an emerging technology, a new measurement procedure, or a laboratory-developed test) or method verification (e.g. when evaluating an established, regulatory-approved commercial measurement procedure) and report the components accordingly. In addition, the analytical performance specifications should be defined *a priori* according to the clinical purpose of the measurement procedure. Appropriate statistical tests and quantitative results should be reported and assessed against the *a priori*-defined analytical performance specification to determine if the measurement procedure fits the intended clinical use.

TABLE 1. Laboratory Evaluation and Analytical Performance Characteristics (LEAP) checklist

Item	No.	Recommendation
Title	1	Indicate whether the study involves a. Method verification of an established commercial measurement procedure, or b. Method validation of a modified/ novel measurement procedure or a laboratory-developed test.
Abstract	2	a. Indicate the key performance characteristics studied. b. Provide numerical absolute and relative results of performance characteristics such as imprecision, bias, and linearity instead of qualitative statements.
Introduction	3	a. For novel technology or measurement procedure, indicate the clinical need it is addressing and the clinical pathway within which it is applied (5,6). b. For existing/commercial technology or measurement procedure, indicate the intended clinical context (e.g., clinical condition, population, clinical pathway) within which the technology or measurement procedure will be applied.

TABLE 1. Continued.

Ethics	4	a. If patient samples or data are being used in the study, indicate whether ethics approval has been sought, or if appropriate, indicate the reason for the waiver. Compliance with the WMA Declaration of Helsinki should be indicated, where relevant (7).
Technology/ measurement procedure	5	a. Describe the technology and/ or measurement procedure used to produce the laboratory results in sufficient detail (<i>i.e.</i> including hardware, calibrator/reagent, procedure/protocol, consumables, and software) to allow independent replication of the results. b. Describe the matrix of the material used and, where relevant, the purity of the materials (<i>e.g.</i> solvent and standards) used. c. Detail the traceability hierarchy of the higher order reference materials used and its measurement uncertainty if such information is available. d. Indicate whether the technology or measurement procedure has received regulatory approval for clinical use, or whether it is limited for research-use only.
Materials used	6	a. Describe the material used for each analytical performance component in the study (<i>e.g.</i> , patient sample, quality control material, external quality assurance material or commercial material), the sample matrix, and if known, the commutability and traceability of the material (demonstrated or otherwise). b. Describe the concentration of the materials used and provide clinical justification for their selection. c. Describe any alteration (<i>e.g.</i> dilution, spiking of material) of the sample, where relevant. d. Describe the stability and storage conditions of the material if relevant.
Experimental designs	7	a. The components of analytical performance evaluation include repeatability and reproducibility imprecision, bias, linearity, analytical measurement interval, clinically reportable interval, dilution factor, limits of quantitation, interference study, method comparison, carryover and stability. Noting the components of the method evaluation varies depending on whether validation or only verification is required. b. Describe the number of replicates, runs and days (particularly for precision studies) over which the evaluation was performed. c. Describe the experimental procedures, including storage conditions and sample preparation, used for each evaluation component.
Analytical performance specification	8	a. Define <i>a priori</i> analytical performance specifications (<i>i.e.</i> acceptance/rejection criteria) for each of the evaluation components with a clear rationale following the Milan consensus (8).
Statistical analysis	9	a. Describe the statistical analysis performed to assess each component of the analytical performance characteristics. b. For statistical analysis involving linear regression, statistical models that are robust regarding heteroscedasticity are preferred. c. Of note, regression characteristics, including slope, intercept, coefficient of coefficient, <i>r</i> , and correlation of determination, R^2 , are not properties of linearity and should not be reported in this context.
Analytical performance characteristics	10	a. Summarise the findings for each evaluation component as stated method section. b. Provide an appropriate numerical summary for the performance characteristics. c. Provide confidence intervals and/or P value if formal statistical testing was performed. d. Use the appropriate significant figures when reporting the data. e. Provide data on proficiency testing performance, especially quantitative data on bias.
Outlier results	11	a. Describe the methods used for detecting outliers, detail number of outliers detected in the study, and whether they were excluded with or without replacement. b. Provide possible reasons for the outlier results that are not due to gross blunders to improve understanding of the measurement procedure.
Interpretation	13	a. Interpret the findings of the evaluation study conservatively in the clinical context where the technology or measurement procedure will be applied. b. Compare the findings of the evaluation study against the <i>a priori</i> -defined analytical performance specification and discuss whether it is fit for purpose.
Limitations	14	a. Report and discuss any relevant limitations in the study design that may influence/restrict/bias the findings. b. Discuss any analytical limitations uncovered during the evaluation study.
Generalisability	15	a. Discuss the findings of the study in the context of existing literature (<i>e.g.</i> , other studies or incumbent technology/measurement procedures).

WMA - World Medical Association.

Discussion

The IFCC WG-MEP has developed and proposed a checklist for using peer-reviewed journals when reporting studies related to method evaluation and analytical performance. The checklist includes essential items on which future studies should be based when publishing their results. This LEAP checklist should be used as a guide for authors, journal editors, and peer reviewers of method evaluation studies to ensure that a study is reported in a comprehensive, transparent, and replicable way.

The Standards for Reporting Diagnostic accuracy studies (STARD) checklist first published in 2003 (revised in 2015) has been widely adopted by peer-reviewed journals reporting diagnostic performances (4). It has contributed to improved standardisation when reporting such results and has facilitated the ability to pool data for meta-analysis. The LEAP checklist has been developed with similar intention focusing on method evaluation following the principles of the EQUATOR initiative (3).

The checklist is specific to the method evaluation. Of note, the establishment and verification of reference intervals are considered outside of the scope of method evaluation for this checklist. Similarly, clinical performance (*i.e.* clinical sensitivity, clinical specificity, accuracy, *etc.*) is also not considered in this checklist and authors are referred to other relevant checklists, such as the STARD 2015

checklist for this information (4). However, regarding method evaluation we consider this checklist to be comprehensive.

In summary, it is envisioned that the LEAP checklist will improve the standardisation of journal publications describing method evaluation and analytical performance characteristics, which will in turn improve the quality of the evidence base that is relied upon by practitioners.

Acknowledgements

We wish to acknowledge the helpful comments provided by the corresponding members of the IFCC WG-MEP that have been incorporated into the published version of the checklist.

Potential conflict of interest

None declared.

Editorial note

This article is simultaneously published in multiple journals in the laboratory medicine field (Clinical Chemistry and Laboratory Medicine, Annals of Laboratory Medicine, Annals of Clinical Biochemistry and Scandinavian Journal of Clinical Laboratory Investigations) with permissions of authors and journals in order to support broad adoption of the LEAP checklist.

References

1. Rifai N, Annesley TM, Berg JP, Brugnara C, Delvin E, Lamb EJ, et al. An Appeal to Medical Journal Editors: The Need for a Full Description of Laboratory Methods and Specimen Handling in Clinical Study Reports. *Scand J Clin Lab Invest.* 2012;72:89-91. <https://doi.org/10.3109/00365513.2011.654052>
2. Hand M, Crampton A, Thomas A, Kilpatrick ES. A survey of clinical laboratory instrument verification in the UK and New Zealand. *Ann Clin Biochem.* 2019;56:275-282. <https://doi.org/10.1177/0004563218823804>
3. UK EQUATOR Centre. How to Develop a Reporting Guideline. Available from: <https://www.equator-network.org/toolkits/developing-a-reporting-guideline/>. Accessed July 18th 2023.
4. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig L, et al. STARD 2015: an updated list of essential items for reporting diagnostic accuracy studies. *BMJ.* 2015;351:h5527. <https://doi.org/10.1136/bmj.h5527>
5. Greaves R, Kricka L, Gruson D, Ferrari M, Martin H, Loh TP, et al. Toolkit for emerging technologies in laboratory medicine. *Clin Chem Lab Med.* 2023 June 14 [cited 2023 Jul 18]. [Epub ahead of print]. <https://doi.org/10.1515/cclm-2023-0571>
6. Monaghan PJ, Robinson S, Rajdl D, Bossuyt PMM, Sandberg S, St John A, et al. Practical guide for identifying unmet clinical needs for biomarkers. *EJIFCC* 2018;29:129-137.
7. WMA Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Available from: <https://www.wma.net/policies-post/wma-declaration-of-helsinki-ethical-principles-for-medical-research-involving-human-subjects/>. Accessed July 18th 2023.
8. Sandberg S, Fraser CG, Horvath AR, Jansen R, Jones G, Oosterhuis W, et al. Defining analytical performance specifications: Consensus Statement from the 1st Strategic Conference of the European Federation of Clinical Chemistry and Laboratory Medicine. *Clin Chem Lab Med* 2015;53:833-5. <https://doi.org/10.1515/cclm-2015-0067>